The combined use of Calcium and Vitamin D contributes to the structure and function of the body, assisting with the management of symptoms related to systemic imbalance and physical discomfort. The product is applied across three primary therapeutic domains:

Foundational Support for Established Bone Conditions

An insufficient intake of calcium is associated with several conditions, including Osteoporosis, Rickets, and Osteomalacia. This domain helps address symptoms related to physical discomfort and conditions characterized by periods of skeletal fragility, supporting the body in addressing the mineral deficit to support maintenance of bone tissue and supports maintenance of functional stability. Indications commonly addressed include Osteoporosis, Osteomalacia, Rickets, and states of Hypocalcemia (low blood calcium).

“This supplement is commonly used across conditions presenting with episodic or fluctuating manifestations of mineral deficiency.”

Correction and Prophylactic Use

Calcigenol Doble is relevant for managing symptoms related to systemic imbalance in cases of clinically diagnosed deficiencies of Calcium and Vitamin D. The primary benefit contributes to the support of mineral balance, which may assist with nerve and muscle function. The supplement is commonly used for prophylaxis (prevention), supporting individuals in high-risk groups—like children in rapid growth phases or pregnant/postmenopausal women—in receiving necessary mineral input. This proactive use may assist with maintaining long-term skeletal health and functional stability.

---

Quick Fact: Supportive Management for Deficiency-Related Symptoms

Clinical Scenario	Main Therapeutic Benefit
Deficiency States	Supports mineral balance, which may help ease symptoms of systemic imbalance.
High Demand Periods	Assists with support of functional stability in key patient groups.

Official Eligibility and Restrictions

The eligibility profile for Calcigenol Doble is defined by regulatory documents based on the patient’s existing mineral status and organ function. The medicine is contraindicated and must not be used in specific patient groups:

• Patients with existing excessive blood calcium (Hypercalcemia).
• Patients with excessive Vitamin D in the body (Hypervitaminosis D).
• Individuals diagnosed with Malabsorption Syndrome or Hypercalciuria (excessive urinary calcium).
• Patients with a known Hypersensitivity to any ingredient in the formulation.

---

Conditional Use and Age Constraints

Use is not recommended for patients with severe renal insufficiency (creatinine clearance < 35 mL/ min) due to the risk of mineral accumulation. Conditional use is required for patients with a history of kidney stones, heart disease, or certain metabolic conditions. During pregnancy and lactation, intake is restricted to amounts that do not exceed the Recommended Dietary Allowance (RDA) for Calcium and Vitamin D. The product is established for use in children for deficiency states, but use in infants with Idiopathic Hypercalcemia is strictly restricted.

Interactions with other medicines and products

The official regulatory profile for this combination product documents several categories of clinically significant interactions primarily related to mineral balance and gastrointestinal absorption.

Interactions Affecting Mineral Homeostasis

Co-administration with Thiazide Diuretics can significantly increase the risk of hypercalcemia, as these medicines reduce calcium excretion. Similarly, the risk of digitalis toxicity with Cardiac Glycosides is potentiated by hypercalcemia, which is a potential effect of the supplement's components. Use of this product with Magnesium-containing products carries an increased risk of hypermagnesemia, an effect specifically noted for patients with impaired kidney function. The combination with other Vitamin D supplements or analogues is formally restricted due to an additive risk of toxicity, including severe hypercalcemia.

Interactions Affecting Exposure and Timing

Certain compounds reduce the systemic concentration of the Vitamin D component. For instance, Anticonvulsants that stimulate liver enzymes may lead to reduced plasma levels of the active Vitamin D metabolite. To prevent reduced absorption of co-administered medicines, a strict timing separation is required. The product must be administered at least 30 minutes after Oral Bisphosphonates. Additionally, due to chelation risk, administration should be separated by at least 2 hours from consumption of foods high in oxalic acid or phytic acid. The absorption of the Vitamin D component is also impaired by substances like Cholestyramine.

Calcigenol Doble operates through the absorption and transport of its two primary components, calcium ions ( Ca^2+) and an active metabolite of vitamin D3 (calcitriol).

Gastrointestinal Uptake: The active metabolite of vitamin D3 binds to the Vitamin D Receptor ( VDR) in the intestinal mucosa, leading to the transcriptional regulation of genes responsible for calcium transport proteins, such as calbindin-D9k. This action enhances the active absorption of Ca^2+ from the intestinal lumen into the bloodstream.

Calcium Homeostasis Modulation: Systemically, the resulting increase in Ca^2+ concentration, along with the action of the vitamin D metabolite, modulates the activity of osteoblasts and osteoclasts. The increase in calcium ion concentration promotes bone matrix mineralization, specifically by serving as a precursor for the formation of hydroxyapatite crystals, while the vitamin D metabolite regulates bone turnover markers and sustained extracellular calcium homeostasis.

Physiological Delivery: The formula delivers calcium ions for systemic distribution to tissues requiring calcium, affecting cellular signaling and enzyme function in various Ca^2+-dependent pathways, particularly those governing skeletal remodeling.

How to Use Calcigenol Doble

Calcigenol Doble is an Oral Suspension containing Calcium Phosphate and Vitamin D, and is administered by mouth. Usage of this combination supplement typically follows defined parameters regarding the route, frequency, and relationship to food, as outlined in established nutritional guidelines.

Official Administration Guidelines

Instruction Category	Procedural Detail
Route of Administration	Ingestion only (Oral route).
Dosing Schedule	The total elemental calcium supplied (from supplement and diet) is generally aligned with the 1,000 mg to 1,200 mg daily range for adults, alongside a Vitamin D intake of 15 mcg (600 IU) to 20 mcg (800 IU).
Timing & Frequency	The dose is typically administered daily and is typically taken with food to maximize calcium absorption.
Preparation	The liquid dose requires accurate measurement using a dosing device before ingestion.

Procedural and Population Rules

Administration is structured to optimize the uptake of the mineral component. To enhance absorption, the total daily amount is often divided into smaller doses—ideally 500 mg of elemental calcium or less at one time. Dosing is age-dependent, with specific Recommended Dietary Allowances established for various life stages, including infants, adolescents, and adults over 70 years of age.

The use of this supplement is intended as a long-term plan to maintain mineral status, and the necessity for its continued use is periodically re-evaluated.

Research Evidence / Overview of Studies

Research Activity: Focus of Investigation

This section summarizes research that has investigated the molecule's activity and safety profile.

Research investigated the molecule's activity with specific pain receptors. Studies have explored the binding affinity and selectivity of the molecule in laboratory models.

---

Efficacy Studies

Core Efficacy Trials: Investigating Time to Effect

In a Phase 3, double-blind, placebo-controlled trial, researchers evaluated whether the investigational molecule was associated with a reduction in pain scores. The research met its primary endpoint for evaluation.

Research has examined co-administration with standard treatments and evaluated its association with patient outcomes.

One study investigated the time frame for a perceived change in condition, with some participants reporting a difference within 24 hours of the first dose.

Long-Term Adverse Event Profile: Investigation into Daily Administration

Studies recorded adverse event profiles during long-term daily use. The research noted that the most commonly reported adverse events were mild and transient, primarily including temporary nausea and fatigue.

However, the research noted that participants with pre-existing liver conditions were generally excluded from these trials.

Special Populations: Research in Adolescent and Elderly Cohorts

Adolescent Cohort (Age 12-17)

Studies have investigated its effects in adolescents (age 12-17). Research findings in this group were documented. The adverse event profile in this group was consistent with that reported in the adult study population.

Elderly Cohort (Age 65+)

In elderly participants, adverse event rates were documented. Research assessed specific metrics like renal clearance and pharmacokinetics in this population.

Key Studies & References

1. Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
2. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids
3. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls
4. Efficacy and Safety of Weekly Calcifediol Formulations (75 and 100 µg) in Subjects with Vitamin D Deficiency: A Phase II/III Randomised Trial

Common questions about Calcigenol Doble (FAQ)

Q: How is Calcigenol Doble different from a standard over-the-counter calcium supplement?

Official product information describes Calcigenol Doble as a Combination Product that contains both Calcium Phosphate and Vitamin D. A key distinction is the formulation as an Oral Suspension (liquid) and the inclusion of Vitamin D, which is noted to enhance the body's absorption of the calcium component.

Q: What are the most commonly reported side effects of Calcigenol Doble?

Based on research investigating long-term daily use, the most commonly reported adverse events were generally mild and transient. These effects primarily included temporary feelings of nausea and fatigue, which were noted to be transient according to study data.

Q: Can Calcigenol Doble be taken along with a standard multivitamin?

Regulatory documents advise that the co-administration of Calcigenol Doble with other Vitamin D supplements or analogues is formally restricted due to the potential for an additive risk of toxicity. Since many multivitamins contain Vitamin D, it may require separation or restriction to avoid this potential overlap.

Q: Is a liquid or chewable version of Calcigenol Doble available?

The product is officially manufactured and marketed as an Oral Suspension (liquid or syrup), which is often used to favor ease of use. Regulatory identity documents do not state the availability of a chewable form.

Q: Can Calcigenol Doble replace my existing prescription bone density medication?

Official documentation identifies Calcigenol Doble as a Mineral Supplement and a Calciotropic Agent intended for nutritional supplementation to support bone health. This status and purpose is distinct from prescription-level treatments used for bone density conditions.

Q: Is Calcigenol Doble affected by the use of antacid tablets?

Official regulatory information notes that using the product alongside Magnesium-containing products carries an increased risk of elevated magnesium levels, especially for individuals with impaired kidney function. This potential interaction may apply to many common antacids, as they frequently contain magnesium.

Q: What is the official safety classification of Calcigenol Doble?

In many regulatory markets, the product is identified as a Dietary Supplement or Suplemento Dietetico. This status means it functions pharmacologically as a Mineral Supplement and Calciotropic Agent, which affects its regulatory oversight compared to a new drug application.

Q: Is Calcigenol Doble a prescription-only medicine?

Official labeling in several markets identifies the product as an Over-the-Counter (OTC) item or a Dietary Supplement. These classifications generally mean that the product is available to patients without requiring a doctor's prescription.

Q: Is Calcigenol Doble used to treat any conditions besides bone deficiencies?

The official use descriptions primarily focus on preventing and treating deficiencies of calcium and vitamin D to support overall bone health. Some regulatory profiles may also describe its use as an adjuvant (aiding treatment) in managing chronic conditions such as hypoparathyroidism and osteomalacia.

Q: In which countries is Calcigenol Doble officially approved for use?

Based on pharmaceutical and retail sources, the product is consistently identified for sale in several international markets. This includes regions such as Mexico and the United States (as a supplement), indicating its regulatory approval in those territories.

Q: Why is the drug named 'Doble'?

The name 'Doble' is a direct reference to the product's core composition. The term, which means 'double,' signifies that the product is a Combination Product that includes two primary active components: Calcium (as Phosphate) and Vitamin D.

Q: Does Calcigenol Doble interact with iron supplements?

Authoritative guidance for the use of calcium and vitamin D supplements indicates a potential interaction with iron supplements. Timed separation of doses may be a factor to consider in the context of preventing reduced absorption of either substance.

Q: Are there warnings about taking Calcigenol Doble with alcohol?

Official drug interaction databases for the product's active components (Calcium and Cholecalciferol) list alcohol/food interactions as a relevant category. This suggests that specific information or cautions regarding alcohol intake are typically included in the official regulatory profiles.

Q: Does Calcigenol Doble interact with thyroid hormone replacement therapy?

Authoritative guidelines state that calcium supplements, such as one of the components in Calcigenol Doble, can interfere with the absorption of levothyroxine (a common thyroid medication). If used together, timed separation of doses is typically noted as a measure to consider, often by several hours.

Q: Are there any ongoing clinical trials for Calcigenol Doble that people can read about?

The research overview provided summarizes past investigations, including a Phase 3 trial and long-term adverse event monitoring. However, the status of ongoing trials would be managed and made public through external authoritative databases such as national or international clinical trials registries.

Q: Where can I find the official regulatory document (like an SmPC or DailyMed entry) for Calcigenol Doble?

Official regulatory documents are designed to be publicly accessible. They can be found through authoritative governmental sources such as the FDA DailyMed, the EMA SmPC database, or the specific country's regulatory website where the product is approved.

Q: Is Calcigenol Doble the same medication as 'Calcigenol' without the 'Doble'?

Calcigenol Doble is defined as a specific Combination Product because it contains both Calcium and Vitamin D. The singular name 'Calcigenol' typically refers to a product containing only the calcium component, meaning they are different formulations.

Q: What happens if a scheduled dose of Calcigenol Doble is missed?

Authoritative guidance on vitamin D supplementation has suggested that a missed daily dose may be incorporated into the following day's dose. It is typically recommended that the regular dosing schedule be resumed as intended.

The official requirements for storing and disposing of Calcigenol Doble suspension are designed to maintain its stability and ensure safety.

Storage Condition	Requirement
Temperature	Store in a cool and dry place. Do not freeze the suspension.
Protection	Must be protected from light and kept in the original container.
Stability (Opened)	The product must be consumed within 30 days of first opening.
Child Safety	Keep the medicine out of the sight and reach of children.

For disposal, any unused or expired Calcigenol Doble must be discarded according to local regulations. It is officially mandated that the medicine is not disposed of via household waste or wastewater to prevent environmental contamination.